<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05612958</url>
  </required_header>
  <id_info>
    <org_study_id>DKM-410-MD-1</org_study_id>
    <nct_id>NCT05612958</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a 'Graft/Prosthesis, Biomaterial (DKM410)' in the Treatment of Both Nasolabial Folds</brief_title>
  <official_title>Efficacy and Safety of a 'Graft/Prosthesis, Biomaterial (DKM410)' in the Treatment of Both Nasolabial Folds: Single Center, Prospective, Comparative, Randomized, Double Blinded (Subject, Evaluator), Matched Pairs Design, Non-inferiority, Pivotal Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongkook Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongkook Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of a 'Graft/prosthesis,&#xD;
      biomaterial (DKM410)' in the treatment of both nasolabial folds.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Actual">June 28, 2022</completion_date>
  <primary_completion_date type="Actual">January 14, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in WSRS(Wrinkle Severity Rating Scale) score by independent evaluators from Baseline to Week 24.</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Independent evaluators evaluate the WSRS score change at Week 24 compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Wrinkle Severity Rating Scale(WSRS) score by independent evaluators from Baseline to Weeks 8, 16 and 48.</measure>
    <time_frame>Baseline and Weeks 8, 16 and 48.</time_frame>
    <description>WSRS(Wrinkle Severity Rating Scale) grading scale from 1 to 5, with grade 1 as absent, grade 2 as mild, grade 3 as moderate, grade 4 as severe, grade 5 as extreme.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of treatment(N%) by independent evaluators from Baseline to Weeks 8, 16, 24 and 48.</measure>
    <time_frame>Baseline and Weeks 8, 16, 24 and 48.</time_frame>
    <description>The percentage of subjects whose WSRS score was lowered by 1 or more points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Wrinkle Severity Rating Scale(WSRS) score by investigator from Baseline to Weeks 8, 16, 24 and 48.</measure>
    <time_frame>Baseline and Weeks 8, 16, 24 and 48.</time_frame>
    <description>WSRS(Wrinkle Severity Rating Scale) grading scale from 1 to 5, with grade 1 as absent, grade 2 as mild, grade 3 as moderate, grade 4 as severe, grade 5 as extreme.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of treatment(N%) by investigator from Baseline to Weeks 8, 16, 24 and 48.</measure>
    <time_frame>Baseline and Weeks 8, 16, 24 and 48.</time_frame>
    <description>The percentage of subjects whose WSRS score was lowered by 1 or more points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) from Baseline to Weeks 8, 16, 24 and 48.</measure>
    <time_frame>Baseline and Weeks 8, 16, 24 and 48.</time_frame>
    <description>Global Aesthetic Improvement Scale (GAIS) from -1 to 3, with grade -1 as worse, grade 0 as no change, grade 1 as improved, grade 2 as much improved, grade 3 as very much improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) after the treatment.</measure>
    <time_frame>Baseline</time_frame>
    <description>Visual Analog Scale (VAS) from 0mm to 100mm, with 0mm as no pain, 100mm as maximum pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>DKM-410</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are injected with an appropriate amount(up to 2.0ml) depending on the degree of nasolabial folds at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Juvederm ULTRA PLUS XC 1.0ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants are injected with an appropriate amount(up to 2.0ml) depending on the degree of nasolabial folds at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DKM-410</intervention_name>
    <description>Injection up to 2.0ml</description>
    <arm_group_label>DKM-410</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juvederm ULTRA PLUS XC 1.0ml</intervention_name>
    <description>Injection up to 2.0ml</description>
    <arm_group_label>Juvederm ULTRA PLUS XC 1.0ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 19 years and older&#xD;
&#xD;
          2. Wrinkle Severity Rating Scale (WSRS) 3 or 4&#xD;
&#xD;
          3. Visually symmetrical bilateral nasolabial folds&#xD;
&#xD;
          4. Agreed not to use any dermatological treatment and wrinkle-improving functional&#xD;
             cosmetics.&#xD;
&#xD;
          5. Voluntarily decided to participate in the study and signed the informed consent form&#xD;
&#xD;
          6. Willing to follow the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of undergoing a permanent or semi-permanent filler treatment on the face&#xD;
&#xD;
          2. Received soft tissue augmentation using HA filler or collagen for nasolabial folds&#xD;
             within 18 months from screening.&#xD;
&#xD;
          3. Received any surgery or laser treatment, chemical filling, heart attack, or Botox&#xD;
             injection within 24 weeks from the screening&#xD;
&#xD;
          4. History of allergic reactions to Hyaluronic Acid or Gram-positive bacteria protein&#xD;
&#xD;
          5. Hypersensitivity to Lidocaine or amide local anesthetic&#xD;
&#xD;
          6. Positive for the intradermal response test&#xD;
&#xD;
          7. History of severe or plurality of allergies&#xD;
&#xD;
          8. Having skin inflammation or infection in nasolabial folds&#xD;
&#xD;
          9. History of keloid formation, hyperpigmentation, or hypertrophic scars on the face.&#xD;
&#xD;
         10. History of streptococcal disease&#xD;
&#xD;
         11. Uncontrolled epilepsy&#xD;
&#xD;
         12. Porphyria&#xD;
&#xD;
         13. Having or being currently suffering from autoimmune diseases&#xD;
&#xD;
         14. History of immunodeficiency or immunosuppressive drugs&#xD;
&#xD;
         15. History of herpetic eruption&#xD;
&#xD;
         16. Having bleeding disorder or blood clotting disorder&#xD;
&#xD;
         17. Having anticoagulant drugs or components within 72 hours from the application of&#xD;
             medical advice&#xD;
&#xD;
         18. Received antiplatelet drugs within 2 weeks from the application of medical advice&#xD;
&#xD;
         19. Having high dose vitamin E or nonsteroidal anti-inflammatory drugs (NSAIDs) and high&#xD;
             dose vitamin C within one week from the application of medical advice&#xD;
&#xD;
         20. Received drugs that inhibit or decrease liver metabolism&#xD;
&#xD;
         21. Clinically significant abnormalities on electrocardiogram&#xD;
&#xD;
         22. Pregnant or breast-feeding or who planning to conceive&#xD;
&#xD;
         23. Clinically severe cardiovascular, digestive, respiratory, endocrine, central nervous&#xD;
             system disorders or mental illness&#xD;
&#xD;
         24. Other investigational products or procedures within 3 months from screening&#xD;
&#xD;
         25. Not eligible due to other reasons at the investigator's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

